apnea has been researched along with Cerebral Palsy, Athetoid in 13 studies
Apnea: A transient absence of spontaneous respiration.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines." | 9.41 | Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023) |
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 9.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 9.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation." | 8.82 | Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. ( Schmidt, B, 2005) |
| "The neurodevelopmental outcome of premature infants with persistent apnea of prematurity (AOP) is reported." | 7.68 | Neurodevelopmental outcome of infants with apnea of infancy. ( Hegyi, T; Hiatt, M; Jadeja, N; Koons, AH; Mojica, N; Ostfeld, B, 1993) |
| " Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines." | 5.41 | Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023) |
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 5.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 5.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation." | 4.82 | Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. ( Schmidt, B, 2005) |
| " Subjects with CP had greater variability and duration of deglutition apnea than controls." | 3.73 | The effect of viscosity on the breath-swallow pattern of young people with cerebral palsy. ( Moussavi, Z; Rempel, G, 2005) |
| " Perioperative complications were postanesthetic seizure and postoperative brief apnea." | 3.71 | [Anesthetic management for laryngotracheal separation and tracheoesophageal diversion]. ( Kujime, Y; Obara, H; Okada, N; Sakai, K; Shiga, M; Takekida, S, 2002) |
| "The neurodevelopmental outcome of premature infants with persistent apnea of prematurity (AOP) is reported." | 3.68 | Neurodevelopmental outcome of infants with apnea of infancy. ( Hegyi, T; Hiatt, M; Jadeja, N; Koons, AH; Mojica, N; Ostfeld, B, 1993) |
| " This study also identified a short-latency apnea that appears to accompany a saliva (protective) swallow and a long-latency apnea that accompanies semi-solid or liquid bolus (alimentary) swallows." | 3.67 | Correlation of ultrasound imaging of oral swallow with ventilatory alterations in cerebral palsied and normal children: preliminary observations. ( Casas, MJ; Kenny, DJ; McPherson, KA, 1989) |
| "Babies with seizures, as well as those with terminal apnoea, were also substantially more likely than controls to have been born after a failure to react appropriately to signs of severe fetal distress during labour." | 2.65 | Adverse outcome of pregnancy and the quality of obstetric care. ( Chalmers, I; Elbourne, D; Henson, G; Macfarlane, A; Niswander, K; Redman, C; Tizard, P, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Marques, KA | 1 |
| Bruschettini, M | 1 |
| Roehr, CC | 1 |
| Davis, PG | 3 |
| Fiander, M | 1 |
| Soll, R | 1 |
| Mohon, RT | 1 |
| Khan, E | 1 |
| DelRosso, LM | 1 |
| Schmidt, B | 3 |
| Anderson, PJ | 1 |
| Doyle, LW | 3 |
| Dewey, D | 1 |
| Grunau, RE | 1 |
| Asztalos, EV | 1 |
| Tin, W | 2 |
| Moddemann, D | 1 |
| Solimano, A | 2 |
| Ohlsson, A | 2 |
| Barrington, KJ | 2 |
| Roberts, RS | 2 |
| Takekida, S | 1 |
| Okada, N | 1 |
| Kujime, Y | 1 |
| Sakai, K | 1 |
| Shiga, M | 1 |
| Obara, H | 1 |
| Rempel, G | 1 |
| Moussavi, Z | 1 |
| Davis, P | 1 |
| Niswander, K | 1 |
| Henson, G | 1 |
| Elbourne, D | 1 |
| Chalmers, I | 1 |
| Redman, C | 1 |
| Macfarlane, A | 1 |
| Tizard, P | 1 |
| Koch, B | 1 |
| Braillier, D | 1 |
| Eng, G | 1 |
| Binder, H | 1 |
| Koons, AH | 1 |
| Mojica, N | 1 |
| Jadeja, N | 1 |
| Ostfeld, B | 1 |
| Hiatt, M | 1 |
| Hegyi, T | 1 |
| Tamura, F | 1 |
| Shishikura, J | 1 |
| Mukai, Y | 1 |
| Kaneko, Y | 1 |
| Rickards, AL | 1 |
| Kelly, EA | 1 |
| Ford, GW | 1 |
| Davis, NM | 1 |
| Callanan, C | 1 |
| Kenny, DJ | 1 |
| Casas, MJ | 1 |
| McPherson, KA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity[NCT01911182] | Phase 2/Phase 3 | 7 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Low recruitment rate) | ||
| Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity[NCT01020357] | Phase 3 | 201 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [NCT01066728] | Phase 2/Phase 3 | 87 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates[NCT03086473] | Phase 4 | 24 participants (Actual) | Interventional | 2017-02-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for apnea and Cerebral Palsy, Athetoid
| Article | Year |
|---|---|
Methylxanthine for the prevention and treatment of apnea in preterm infants.
Topics: Apnea; Caffeine; Cerebral Palsy; Disabled Persons; Humans; Infant; Infant, Newborn; Infant, Prematur | 2023 |
Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial.
Topics: Aging; Apnea; Blindness; Cerebral Palsy; Cognition Disorders; Deafness; Follow-Up Studies; Humans; I | 2005 |
3 trials available for apnea and Cerebral Palsy, Athetoid
| Article | Year |
|---|---|
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Adverse outcome of pregnancy and the quality of obstetric care.
Topics: Adolescent; Apnea; Asphyxia Neonatorum; Birth Injuries; Cerebral Palsy; Clinical Trials as Topic; En | 1984 |
8 other studies available for apnea and Cerebral Palsy, Athetoid
| Article | Year |
|---|---|
Increasingly Familiar Breathing Pattern in an Unfamiliar Population. Sleep-related Breathing Disorders in High-Risk Patients.
Topics: Apnea; Baclofen; Cerebral Palsy; Child; Female; Humans; Polysomnography; Sleep; Sleep Apnea, Central | 2020 |
[Anesthetic management for laryngotracheal separation and tracheoesophageal diversion].
Topics: Adolescent; Anastomosis, Surgical; Anesthesia, General; Apnea; Cerebral Palsy; Child; Child, Prescho | 2002 |
The effect of viscosity on the breath-swallow pattern of young people with cerebral palsy.
Topics: Adolescent; Adult; Analysis of Variance; Apnea; Case-Control Studies; Cerebral Palsy; Deglutition; D | 2005 |
Computerized tomography in cerebral-palsied children.
Topics: Adolescent; Apnea; Brain; Cerebral Palsy; Child; Child, Preschool; Hemiplegia; Humans; Infant; Infan | 1980 |
Neurodevelopmental outcome of infants with apnea of infancy.
Topics: Apnea; Cerebral Palsy; Child, Preschool; Developmental Disabilities; Female; Follow-Up Studies; Huma | 1993 |
Arterial oxygen saturation in severely disabled people: effect of oral feeding in the sitting position.
Topics: Adolescent; Adult; Airway Obstruction; Apnea; Blood Circulation; Cerebral Palsy; Cough; Disabled Per | 1999 |
Methylxanthines and sensorineural outcome at 14 years in children < 1501 g birthweight.
Topics: Adolescent; Apnea; Bronchodilator Agents; Cerebral Palsy; Child Development; Developmental Disabilit | 2000 |
Correlation of ultrasound imaging of oral swallow with ventilatory alterations in cerebral palsied and normal children: preliminary observations.
Topics: Apnea; Cerebral Palsy; Deglutition; Humans; Respiration; Ultrasonography | 1989 |